30 March 2023 in Molecules and Cells
Aryatara Shakya, Nicholas W. McKee, Matthew Dodson, Eli Chapman, and Donna D. Zhang. Mol. Cells 2023;46:165-75. https://doi.org/10.14348/molcells.2023.0005
24 January 2026 in Redox Biology
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is best known for its regulation of the antioxidant response. However, its mediation of other pathways, including key aspects of metabolic and protein homeostasis, has continued to emerge. Accompanying this emergence is an evolved understanding that NRF2 induction across different disease contexts can be beneficial or detrimental depending on the length of activation. This has played an important role in progressing the field forward, as inducing NRF2 is not always the best course of action, and inhibition has gained traction as a viable strategy for treating cancer and other pathologies where NRF2 is chronically active. Despite its rapid growth and a wealth of experimental promise, a persistent shortcoming in the field is a lack of NRF2-specific therapeutics used in clinic. Thus, despite recent advances, there is still room for progress in translating experimental evidence into therapeutic reality. In this review, we will provide a summary of NRF2 regulation and an update on its expanded network of downstream transcriptional programs. We will also discuss targeting NRF2 in disease, focusing on intervention versus prevention depending on the pathological context. Finally, we will briefly highlight current limitations in the field, as well as ongoing approaches that show promise for finally targeting this critical cascade in patient populations.
8 June 2023 in Nature Cell Biology
1 April 2013 in The FASEB Journal
Neurodegeneration are associated with multiple hits at metabolic pathways including those involved in metabolism (mitochondria and glycolysis) cell signaling (Keap1‐Nrf2 or apoptosis) or cell repair pathways (fission/fusion and autophagy). We investigated the regulation of autophagy in neuronal response to oxidative and nitrative stress. 4‐hydroxynonenal (HNE) is a lipid peroxidation product formed during oxidative stress, accumulated in neurodegenerative diseases, and can further induce formation of other reactive species. DETA‐NONOate is a nitric oxide donor, used to mimick excessive nitric oxide produced by both neurons and glia in neurodegeneration. We found that HNE and DETA‐NONOate decrease mitochondrial oxygen consumption. Interestingly, HNE inhibited, and DETA‐NONOate stimulated glycolysis. The glycolysis response was inversely correlated with autophagy, as HNE stimulated and DETA‐NONOate inhibited autophagy. To investigate how glucose metabolism and autophagy play a role in mitochondrial quality control and cell death, we blocked glycolysis using 2‐DG, and found that 2‐DG abolished glycolysis, decreased mitochondrial reserve capacity, inhibited autophagy and exacerbated HNE‐ and DETA‐NONOate‐induced cell death. Inhibition of autophagy by 3‐MA, while increased glycolysis which is in contrary to 2‐DG, decreased mitochondrial reserve capacity and exacerbated HNE‐ and DETA‐NONOate‐induced cell death, effects similar to 2‐DG. Moreover, we found that 2‐DG played an important role in regulation of Bcl‐2 expression and 3‐MA played an important role in regulation of Drp1 and JNK activity. Our studies provide novel insights into how regulation of autophagy and glucose metabolism plays an important role in neuronal bioenergetics and survival in response to oxidative and nitrative stress. Funded by NIH and VA.